[
  {
    "company_name": "The Cigna Group",
    "symbol": "CI",
    "overall_sentiment": "positive",
    "financials": {
      "eps_change": "increased to 10% to 14%",
      "outlook_summary": "expects strong rates of growth for the next several years despite a disrupted environment."
    },
    "executives": [
      {
        "name": "Brian Evanko",
        "role": "CFO",
        "sentiment": "positive"
      },
      {
        "name": "Kevin Fischbeck",
        "role": "Analyst",
        "sentiment": "neutral"
      }
    ],
    "technologies": [
      {
        "technology_name": "AI",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "long-term",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "unclear"
      },
      {
        "technology_name": "Cloud Computing",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "long-term",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "unclear"
      }
    ],
    "year": 2024,
    "quarter": 1,
    "date": "2024-05-15 08:30:00"
  },
  {
    "company_name": "The Cigna Group",
    "symbol": "CI",
    "overall_sentiment": "positive",
    "financials": {
      "revenue_growth": "+25%",
      "eps_change": "+10%",
      "outlook_summary": "Full year 2024 adjusted EPS outlook of at least $28.40, representing more than 13% year-over-year growth."
    },
    "executives": [
      {
        "name": "Ralph Giacobbe",
        "role": "Senior Vice President of Investor Relations",
        "sentiment": "neutral"
      },
      {
        "name": "David Cordani",
        "role": "Chairman and Chief Executive Officer",
        "sentiment": "positive"
      },
      {
        "name": "Brian Evanko",
        "role": "Chief Financial Officer and President and Chief Executive Officer of Cigna Healthcare",
        "sentiment": "positive"
      },
      {
        "name": "Eric Palmer",
        "role": "President and Chief Executive Officer of Evernorth Health Services",
        "sentiment": "neutral"
      }
    ],
    "technologies": [
      {
        "technology_name": "Biosimilars",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "David Cordani"
      }
    ],
    "year": 2024,
    "quarter": 2,
    "date": "2024-08-01 08:30:00"
  },
  {
    "company_name": "The Cigna Group",
    "symbol": "CI",
    "overall_sentiment": "positive",
    "financials": {
      "revenue": "$63.7 billion",
      "eps": "$7.51",
      "full_year_eps_outlook": "at least $28.40",
      "revenue_growth": "strong",
      "eps_change": "more than 13% year-over-year growth",
      "outlook_summary": "expects full-year 2024 adjusted EPS of at least $28.40, representing more than 13% year-over-year growth. Expects 2025 EPS growth of at least 10%."
    },
    "executives": [
      {
        "name": "Brian Evanko",
        "role": "Chief Financial Officer and President and Chief Executive Officer of Cigna Healthcare",
        "sentiment": "positive"
      },
      {
        "name": "David Cordani",
        "role": "Chairman and Chief Executive Officer",
        "sentiment": "positive"
      },
      {
        "name": "Ralph Giacobbe",
        "role": "Senior Vice President of Investor Relations",
        "sentiment": "neutral"
      },
      {
        "name": "Eric Palmer",
        "role": "President and Chief Executive Officer of Evernorth Health Services",
        "sentiment": "neutral"
      }
    ],
    "technologies": [
      {
        "technology_name": "Pharmacological innovation",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "long-term",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Brian Evanko"
      },
      {
        "technology_name": "Biosimilars",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+unclear",
        "mentioned_by": "Brian Evanko"
      },
      {
        "technology_name": "Humira biosimilars",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+unclear",
        "mentioned_by": "Brian Evanko"
      }
    ],
    "year": 2024,
    "quarter": 3,
    "date": "2024-10-31 08:30:00"
  },
  {
    "company_name": "The Cigna Group",
    "symbol": "CI",
    "overall_sentiment": "neutral",
    "financials": {
      "revenue_growth": "6%",
      "eps_change": "negative",
      "rd_investment_change": "unclear",
      "outlook_summary": "Expects full year 2025 consolidated adjusted revenues of at least $252 billion. Full-year 2024 consolidated adjusted revenues were $247.1 billion, with adjusted after-tax earnings of $7.7 billion and adjusted EPS of $27.33. Full-year 2024 MCR was 83.2%, above guidance. Expects to recapture approximately 100 basis points of margin in Cigna Healthcare over the next two years."
    },
    "executives": [
      {
        "name": "Brian Evanko",
        "role": "CFO and President and CEO of Cigna Healthcare",
        "sentiment": "neutral"
      },
      {
        "name": "David Cordani",
        "role": "Chairman and CEO",
        "sentiment": "neutral"
      },
      {
        "name": "Eric Palmer",
        "role": "President and CEO of Evernorth Health Services",
        "sentiment": "neutral"
      },
      {
        "name": "Ralph Giacobbe",
        "role": "Senior Vice President of Investor Relations",
        "sentiment": "neutral"
      }
    ],
    "technologies": [
      {
        "technology_name": "Specialty Medications",
        "technology_sentiment": "positive",
        "investment_action": "unclear",
        "investment_horizon": "unclear",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Brian Evanko"
      },
      {
        "technology_name": "Humira biosimilars",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "+18%",
        "mentioned_by": "Brian Evanko"
      }
    ],
    "year": 2024,
    "quarter": 4,
    "date": "2025-01-30 08:30:00"
  }
]